



GlaxoSmithKline Pharmaceuticals Profits up by 12% in First Quarter of FY 2008

Mumbai 21st April, 2008: GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the first quarter ended 31st March, 2008. The Company has posted a Profit before tax growth of 12% compared to the previous quarter, while net sales have grown by 5.3% on a comparable basis.

Commenting on the performance, Dr. Hasit B. Joshipura, Managing Director, said “During the quarter, priority products have grown by 9%. Sales of price controlled products have been impacted by excise drops which are being passed on and the consequent price adjustment due to these changes. We intend to pass on the effect of excise changes across the portfolio”. He further added, “We are also well positioned to launch the breast cancer drug, Tykerb and the rotavirus vaccine, Rotarix during the year.”

About GlaxoSmithKline:

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com.

For enquiries, please contact:

Sunder Rajan
General Manager, Corporate Communications

+91 22 24959203
sunder.r.rajana@gsk.com

April 21, 2008